6th Conference on Retroviruses and Opportunistic Infections


Chicago, IL - January 31-February 4, 1999



Phase I study of the safety and immunogenicity of an ALVAC vaccine in children born to HIV infected mothers: preliminary

Results:

Conf Retroviruses Opportunistic Infect 1999 Jan 31-Feb 4; 6th:75 (abstract no. 43)

Johnson D, McFarland E, Kang M, Fenton T, McNamara J, Hawkins E, Starr S, Bouquin P, El Habib R, Excler JL, Read J, Lambert J
Results: 12 newborns have been enrolled, 5 each in cohorts 1 and 2, and 2 in cohort A. 8 have received 4 doses, one-3 doses, one-2 doses and two-1 dose. None experienced significant (≥ grade 3) vaccine associated local or systemic complications. Blinded LP data through week 6 is available for 7 subjects. At wk 0, 1/5, 0/4, and 2/4 subjects responded, and at wk six 3/7, 3/7, and 4/7 subjects responded to p24, gp160, and ALVAC antigens respectively. Subjects with a week 6 response to p24 also responded to gp 160 and ALVAC with a marked increase in SI from baseline.

Conclusions: Preliminary pediatric data suggest vCP205 is safe. It is immunogenic in some subjects. vCP205 may have a role in post-exposure prophylaxis.

Keywords: AEGIS, Viral Vaccines, HIV-1, Safety, Gene Products, gag, Mothers, ALVAC vaccine, Child, Human, Adult, Infant, Infant, Newborn, pathogenicity, AIDSKWDaegis,viralvaccines,hiv-1,safety,geneproducts,gag,mothers,alvacvaccine,child,human,adult,infant,infant,newborn,pathogenicity,aids

1999-01-31
43

Copyright © 1999 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed from National Library of Medicine.